Is there a role for phenotyping patients with CSU outside of a research setting by ordering IgG-anti-TPO, IgG-anti-FceRI , total IgE, total IgA etc.?

I do think it can be helpful in patients who have difficult-to-control disease. Many of these (e.g. IgG-anti-TPO, total IgE, anti-thyroglobulin antibody) have been shown to help predict responsiveness to omalizumab treatment or have been associated with disease activity (Højgaard Pedersen et al., PM...